tbuckley/cabot-search huggingface dataset:
Prevención de la transmisión de los Staphylococcus aureus resistentes a la meticilina (SARM) en la población general
Authors: F Vandenesch, J Etienne
Journal: Eurosurveillance (2004)

Durante los ultimos 20 a 30 anos, las cepas de Staphylococcus aureus resistentes a la meticilina (SARM) han estado presentes en los hospitales, convirtiendose en una de las principales causas de las infecciones nosocomiales. La tasa de resistencia a la meticilina de los S. aureus varia considerablemente de un pais a otro, teniendo los Estados Unidos y el sur de Europa una prevalencia elevada (g20%) y el norte de Europa una prevalencia baja (l o =5%). Los SARM adquiridos en la comunidad (CA-SARM) emergieron en todo el mundo al final de los anos 90. Hubo una gran confusion en la literatura entre las infecciones por SARM asociadas a cuidados sanitarios en la poblacion general en pacientes a riesgo para infecciones nosocomiales a SARM (como los pacientes que ya fueron hospitalizados en el pasado, o los que presentan una deficiencia inmunitaria, etc), y las verdaderas infecciones CA-SARM debidas a cepas presentes unicamente en la comunidad.
Anti HER2 treatment (H) in the elderly: a “real life” retrospective analysis
Authors: A. Malossi, O.E. Cursio, G. Courthod, B. Thiebat, A. Battaglia, A. Mozzicafreddo, M. Cucchi, M.R. Alvaro, M. Sicuro, M. Schena
Journal: Annals of Oncology (2017)
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Authors: Hongchao Pan, Richard Gray, Jeremy Braybrooke, Christina Davies, Carolyn Taylor, Paul McGale, Richard Peto, Kathleen I. Pritchard, Jonas Bergh, Mitch Dowsett, Daniel F. Hayes
Journal: New England Journal of Medicine (2017)

The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending such therapy beyond 5 years offers further protection but has additional side effects. Obtaining data on the absolute risk of subsequent distant recurrence if therapy stops at 5 years could help determine whether to extend treatment.
PALL-01. ONE YEAR WITH OPTUNE® IN AUSTRIA: FIRST REPORT ON CLINICAL OUTCOMES
Authors: Johannes Kerschbaumer, Daniel Pinggera, Claudius Thomé, Christian Freyschlag
Journal: Neuro-Oncology (2017)

Tumor Treating Fields (TTFields) consist of alternating electric fields that are delivered via 4 transducer arrays placed on the shaved scalp. Optune TTField treatment is an established, non-invasive therapy for patients with newly diagnosed or recurrent glioblastoma (GBM). Treatment efficacy was evaluated in the EF-14 trial demonstrating significant improvement of both, overall and progression free survival. Fourteen patients with newly diagnosed (N=10) and recurrent GBM (N=4) were the first to receive TTFields in Austria (starting in February 2016) and received a prescription in our department. Our population included 4 female and 10 male patients with a mean age of 48 years (range 17-68 years). The mean treatment time amounted to 5 months (range 2 weeks - 14 months). The disease remained stable in 9 patients with a mean treatment rate of 82,3% daily. Three patients (21 %) showed progression, two with a surgically resectable recurrence, one with a diffuse progression of the disease. With regards to the side effects we were faced with mild to moderate skin irritation (RTOG 0-1) in 2 patients, but those could be treated by local steroids. Treatment was interrupted in one patient. We noticed that patients needed approximately 4 weeks to adapt to the therapy. The compliance rate assessed by patient’s feedback, show that patients mostly accept this new treatment approach. TTFields are generally accepted as an efficacious treatment of GBM. Our experiences with TTFields are widely positive with great acceptance of TTFields by the patients. However, reported results pertain to a short treatment time and need to be validated for a longer time.
METB-09. METABOLIC ADAPTATION TO CHRONIC HYPOXIA IN GLIOBLASTOMA CELLS
Authors: Laura Caflisch, Alessia Lodi, Aleksandra Gruslova, David Cavazos, Michael Garcia, Stefano Tiziani, Andrew Brenner
Journal: Neuro-Oncology (2017)

Long-term metabolic adaptations may account for the ability of GBM tumor cells to adapt to the stress of hypoxia over time to survive and grow aggressively. Our patient-derived GBM cells grow more aggressively in vitro during long-term hypoxia compared to normoxia despite initial stress. This suggests that these cells can adapt directly to hypoxic environments over time, rather than simply relying on evasion of hypoxia through angiogenesis and migration. Cells were cultured in 2% hypoxia for at least 2-5 weeks. Using mass spectrometry, NanoSight extracellular vesicle analysis, and metabolic inhibitors, metabolic patterns associated with hypoxia were determined, with focus on lipid metabolism. In addition, patient tumors with previously quantified hypoxic burdens (using carbonic anhydrase IX) were profiled for lipid metabolites. In vitro metabolite levels supported an expected increased flux of metabolites through anaerobic glycolysis (p<0.0013 for increased G3P and lactic acid) and decreased flux through the citric acid cycle (p=0.027 for decreased malic acid) during hypoxia compared to normoxia, as well as decreased flux through mitochondrial fatty acid oxidation (p<0.0033 for increased isobutyryl-L-carnitine, L-acetylcarnitine, hexanoylcarnitine), increased flux through glutathione metabolism (p<0.000057 for increased S-lactoylglutathione, decreased glutathione), and an overall decrease in cardiolipins and gangliosides (p<0.0062). Patient tumors with higher hypoxic burdens were correlated with a decrease in very long chain fatty acids in the serum (r2=0.50). The metabolic inhibitor TVB (fatty acid synthase inhibitor) induced an increase in extracellular vesicles, with an increased proportion of exosome-sized vesicles (50-120 nm) specifically during hypoxia (p=0.042). These findings reflect changes in metabolic pathways, including lipid metabolism, the citric acid cycle, fatty acid oxidation, glutathione recycling, and extracellular vesicle synthesis, that could be potentially targeted to increase the sensitivity of hypoxic tumors to treatment, particularly in combination with treatments that increase hypoxia such as anti-angiogenic agents.
P3.02-051 Low Consistency Between FGFR1 Gene Amplification and Protein Expression in Squamous Cell Lung Cancer (SQCLC)
Authors: J. Chorostowska-Wynimko, M. Skupinska, A. Rozy, K. Siewiera, E. Szczepulska, R. Langfort, P. Rudzinski, T. Orlowski, M. Wieczorek, A. Stanczak
Journal: Journal of Thoracic Oncology (2017)
Prevalence of KRAS, NRAS and BRAF mutations detected by massive parallel sequencing and differential clinical outcome in metastatic colorectal cancer (MCRC) patients (pts) treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy
Authors: G. Bruera, F. Pepe, U. Malapelle, P. Pisapia, A. Dal Mas, D. Di Giacomo, G. Calvisi, G. Troncone, E. Ricevuto
Journal: Annals of Oncology (2017)
How can molecular heterogeneity impact on treatment choice in advanced colorectal cancer?
Authors: G. De Maglio, E. Ongaro, N. Pella, S. Ciani, S. Cernic, M. Giovannoni, P. Ermacora, G.G. Cardellino, D. Iacono, G. Aprile, S. Pizzolitto, G. Fasola
Journal: Annals of Oncology (2017)
David Oliver: An argument against more NHS funding? I don’t buy it
Authors: David Oliver
Journal: BMJ (2017)

The NHS faces an unprecedented financial crisis. A Nuffield Trust report has shown a deficit of £3.7bn in acute trusts, compared with a target of £580m set by NHS England.1 The King’s Fund found in June that 43% of NHS finance directors planned to overspend their budget this financial year.2 It also found that 50% of clinical commissioning group finance leads would have to delay or cancel spending to achieve the set financial “control totals.”2

NHS performance is stalling or falling in several key areas.23 Independent analyses of sustainability and transformation partnerships (STPs) have questioned their ability to deliver anything like the scale of savings they promise.456 The Office for Budget Responsibility forecasts that NHS spending per person will fall …
Subsite-dependent prognostic impact of age in patients with nasopharyngeal and oropharyngeal cancer
Authors: R. Granata, E. Orlandi, G. Infante, N.A. Iacovelli, R. Miceli, A. Cavallo, S. Alfieri, C. Bergamini, C. Resteghini, D. Galbiati, S. Cavalieri, L. Locati, S. Tana, S. Naimo, C. Fallai, L. Licitra, P. Bossi
Journal: Annals of Oncology (2017)
P2.02-028 Prognostic Value of Cox-2 Expression Differs Depending on CD8+ T Lymphocytes and PD-L1 Expression in Resected Lung Adenocarcinoma
Authors: K. Shimizu, R. Okita, S. Saisho, A. Maeda, Y. Nojima, M. Nakata
Journal: Journal of Thoracic Oncology (2017)
Epidemiología das infecções associadas a Streptococcus pyogenes na Europa
Authors: T L Lamagni, A Efstratiou, J Vuopio-Varkila, A Jasir, C Schalén
Journal: Eurosurveillance (2005)

No final dos anos 80, varios paises europeos notificaram surtos de uma doenca grave produzida por Streptococcus pyogenes. Foi o que marcou o inicio de um novo periodo depois das decadas passadas, onde foram notificados muito poucos surtos com estas caracteristicas. Essas mudancas na ocorrencia da doenca fazem parte de um fenomeno global, cujas razoes ainda estao por ser explicadas. Os resultados da vigilância das infeccoes invasivas por S. pyogenes na Europa nos ultimos 15 anos identificaram um aumento em muitos paises. Por entanto, as diferencas entre os metodos de vigilância dos paises em toda Europa impedem comparacoes validas, porem que mostra a necessidade de uma estrategia unificada . O Programa Strep-EURO foi introduzido em 2002 para responder a essa necessidade.
Re: Ken J. Kron, Alexander Murison, Stanley Zhou, et al. TMPRSS2–ERG Fusion Co-opts Master Transcription Factors and Activates NOTCH Signaling in Primary Prostate Cancer. Nat Genet 2017;49:1336–45
Authors: Giovanni Lavorgna, Francesco Montorsi, Andrea Salonia
Journal: European Urology (2017)
Challenges in Implementing Personalized Care Planning
Authors: Gemmae M. Fix, Rendelle E. Bolton, Barbara G. Bokhour
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TMOD-01. AUTOMATED PATH TRACKING INCREASES THE UTILITY AND SCALABILITY OF HUMAN ORGANOTYPIC SLICE CULTURE FOR STUDY OF GLIOBLASTOMA MIGRATION
Authors: Lauren Gardiner, Vashali Jain, Shiva Krishnan, Masood Sadaat, Jonathan Parker, Allen Waziri, Kara Foshay
Journal: Neuro-Oncology (2017)

Invasion of tumor cells through the brain remains a significant challenge for treating glioblastoma (GBM). In an effort to better target this phenomenon, we developed a technique for organotypic slice culture of human GBM, which when used in combination with GFP retroviral transduction and time-lapse confocal microscopy allows for observation of migrating tumor cells within an ex vivo three-dimensional architecture. Our prior studies with this model utilized manual tracking to calculate speed and directionality of cell movement. However, this complicated method is labor intensive, requires a skilled analyst, and leads to lack of scalability. Therefore, an automated method for migration analysis would significantly enhance the utility of the slice model platform for larger-scale experimentation. In the current study, we use our prior data to compare our manual tracking paradigm with the automated path tracking platform ImageJ running the ADAPT plugin. Allowing for optimization of parameters critical for cell identification, including GFP fluorescence intensity, object size, and minimum trajectory, ADAPT can detect both changes in membrane morphology and cell migration. Using this comparative approach, we demonstrated that on average ADAPT tracks two-fold more cells with a 97% decrease in time required for analysis. Although absolute migration speeds varied between manual and automated path-tracking methods by approximately 20%, ADAPT analysis of blinded samples reproduced previously identified statistically significant gefitinib-induced decreases in migration speed seen specifically within EGFR amplified tumors. These data suggest potent utility for ADAPT as an unbiased and robust method for analysis of cell migration in patient-derived GBM slice culture.
P3.13-031 Predicting Factor for the Dissociation of the Diameter Between Radiographical Solid Part and Pathological Invasive Part in Lung Adenocarcinoma
Authors: Y. Suzuki, M. Yotsukura, T. Ohtsuka, S. Kuriyama, H. Sakamaki, K. Masai, K. Kaseda, T. Hishida, Y. Hayashi, K. Emoto, H. Asamura
Journal: Journal of Thoracic Oncology (2017)
EXTH-75. IMAGING GLIOBLASTOMA STEM CELLS WITH 7-AMINO ACID-LENGTH TUMOR-HOMING PEPTIDE IDENTIFIED BY PHAGE DISPLAY BIOPANNING
Authors: Jongmyung (John) Kim, Jeremy Rich, James Liu
Journal: Neuro-Oncology (2017)

One of the most promising strategies to treat cancer is the specific delivery of theranostic reagents to tumor-initiating and chemoradiation-resistant cell populations for early diagnosis and eradication of tumor cells with minimizing toxicity to normal tissues. Glioblastoma stem cells have earned a great deal of focus due to their pivotal role in GBM tumorigenesis and therapeutic resistance. To further develop strategies to more specifically detect and target this subpopulation of tumor cells, we employed a phage display (PhD) biopanning against glioblastoma stem cells (GSCs) to isolate tumor-homing peptides. In vitro and in vivo screening on GSCs isolated from patient GBM tumors with PhD library of 7-amino acid-length peptides recovered a consensus peptide, GBMIC2, which demonstrated strong GSC-specific affinity. To achieve efficient signal penetration through skull bone and reduce autofluorescence in biological tissues during in vivo imaging, we utilized near-infrared (NIR) fluorescence with a cyanine 5.5-conjugated synthetic peptide (GBMIC2-Cy5.5). The specificity of the synthetic peptide for GSCs was confirmed by flow cytometry analysis and immunocytochemistry. GBMIC2-Cy5.5 was delivered to subcutaneous or intracranial GBM patient-derived xenograft (PDX) models via intravenous injections. Tumor specificity and dynamics of fluorescence signals were monitored and analyzed using IVIS SpectrumCT In Vivo Imaging System for 72 hours. Signals were highly specific and constant to xenografted tumors with a low intensity from normal brain and surrounding tissues. Immunohistochemistry analysis of xenografted tumors confirmed that GBMIC2-Cy5.5 was specific for tumor cells and was localized to the perivascular niche. These data corresponded to previous results matching GBMIC2 with EYA1, a protein involved in tumor cell proliferation and migration, that also localized to perivascular niche. These studies confirm the applicability of phage display biopanning to isolate tumor tropic peptides, and that GBMIC2 has the potential to selectively target GSCs for imaging and anticancer drug delivery for GBM treatment.
Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens
Authors: Liga Kuksa, Linda Barkane, Norbert Hittel, Rajesh Gupta
Journal: European Respiratory Journal (2017)

Latvia is a high-priority country in the fight against tuberculosis (TB) in Europe, with an estimated TB incidence of 41 per 100 000 in 2015 [1]. In spite of an improving TB control programme [2] and cure rates reaching 80% for new and retreatment TB cases notified in 2014, multidrug-resistant (MDR-) TB (defined as TB resistant to rifampicin and isoniazid) rates in Latvia remain high [1]. An estimated 8% of new cases and 30% of retreatment TB cases were at least rifampicin-resistant (RR) in 2015 [1]. Cure rates in Latvia were 68% for the 2013 RR/MDR-TB cohort [1]. Of all the MDR-TB patients registered in 2015, 25% had extensively drug-resistant (XDR-) TB (defined as MDR-TB with additional resistance to a fluoroquinolone and a second-line injectable drug) [1]. Final treatment outcomes from the first cohort of delamanid MDR-TB patients in Latvia support its safety and efficacy <http://ow.ly/6Mhy30fPv2f>
Il controllo della rosolia in Italia
Authors: M L Ciofi Degli Atti, A Filia, M G Revello, W Buffolano, S Salmaso
Journal: Eurosurveillance (2004)

In Italia la vaccinazione antirosolia e raccomandata per le ragazze prepuberi dal 1972, e per tutti i bambini nel secondo anno di vita dai primi anni '90. Tuttavia, la copertura vaccinale nazionale dei bambini tra 12 e 24 mesi di eta e ancora insoddisfacente (56% nel 1998, 78% nel 2003), e presenta ampie differenze tra regioni.
Di conseguenza, la rosolia continua a circolare nel paese e nel 1996 la proporzione di donne tra 15 e 39 anni suscettibili all'infezione era superiore al 5%. 
La sindrome da rosolia congenital (SRC) e stata soggetta ha notifica obbligatoria negli anni 1987-1991, con un range di 8-76 casi segnalati annualmente. Dal 1992 non sono piu disponibili dati nazionali, tuttavia vi sono dati locali che mostrano come la SRC sia tuttora presente. 
Per controllare in maniera efficace la SRC e necessario attuare delle azioni coordinate su tutto il territorio nazionale. Per questo, e stato recentemente approvato il Piano nazionale di eliminazione del morbillo e della rosolia congenita, che include sia strategie mirate ad aumentare la copertura vaccinale per MPR nei bambini, che azioni specifiche per il controllo della SRC. Queste ultime prevedono il miglioramento della vaccinazione delle donne in eta fertile suscettibili, e la reintroduzione a livello nazionale della sorveglianza della SRC.
ACTR-15. THERAPEUTIC KETOGENIC DIET (KD) WITH RADIATION AND CHEMOTHERAPY FOR NEWLY DIAGNOSED GLIOBLASTOMA – PRELIMINARY RESULTS FROM NCT02046187
Authors: Chris Dardis, Leonora Renda, Norissa Honea, Kris Smith, Peter Nakaji, Lynn S Ashby, Adrienne C Scheck
Journal: Neuro-Oncology (2017)

The KD shows promise as a treatment for glioblastoma (GB). Pre-clinical studies show potentitation of radiation and chemotherapy, enhanced anti-tumor immune-reactivity and a reduction in peri-tumoral edema, angiogenesis and hypoxia. It appears safe and tolerable, based on its use in the treatment of epilepsy and increasingly, by athletes/bodybuilders. This was a single-institution trial. Under supervision of a Registered Dietician Nutritionist (RDN), patients followed a classic 4/1 (energy ratio, fat/ protein + carbohydrates) KD during radiation (RT, 6 weeks) and temozolomide (TMZ). Ketosis was verified by measurements of ketones and glucose. Thereafter, they were encouraged to follow a modified Atkins diet (1/1). We also include results from a number of patients who underwent identical treatment, but were not enrolled on the trial. 30 patients were approached and 14 patients enrolled on the trial; 2 stopped treatment prior to completion of RT due to tolerability. No weight loss of >10% baseline occurred. Nausea was reported by 4/14. There were no other significant adverse events. On an intention-to-treat basis, median time-to-progression (TTP) was 7 months and overall survival (OS) 29.3 months. In the 20 patients in total using the regimen, TTP and OS were 6.6 and 22 months. Additional analyses including comparisons with matched historic controls and molecular prognostic factors are in progress. The therapeutic KD appears safe. It is generally tolerable for the duration of radiotherapy. It is not practical for every patient and longer-term use is likely to be challenging. Close support from clinical personnel, particularly the RDN, is crucial. Preliminary results are encouraging. A trial of the KD in recurrent GB is planned.
MA 01.03 The Potential of ctDNA Sequencing in Disease Monitoring and Depicting Genomic Evolution of Small-Cell Lung Cancer Under Therapy
Authors: J. Wang, Y. Gong, J. Nong, Y. Yi, Y. Guan, L. Yang, H. Jia, S. Zhang, X. Yi, Z. Liao, V. Lam, V. Papadimitrakopoulou, I. Wistuba, J. Heymach, B. Glisson, A. Futreal, X. Xia, J. Zhang
Journal: Journal of Thoracic Oncology (2017)
Robert Chesebrough and the Dermatologic Wonder of Petroleum Jelly
Authors: Kishore L. Jayakumar, Robert G. Micheletti
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal